66922-69-8

Basic information

• Product Name: 5'-Methoxy-3',4'-methylenedioxyacetophenone
• Synonyms: 5'-Methoxy-3',4'-methylenedioxyacetophenone
• CAS NO: 66922-69-8
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.184
• Mol File: 66922-69-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 320°Cat760mmHg
• Flash Point: 142.4°C
• Appearance: /
• Density: 1.243g/cm³
• Vapor Pressure: 0.000326mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 5'-Methoxy-3',4'-methylenedioxyacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-Methoxy-3',4'-methylenedioxyacetophenone(66922-69-8)
• EPA Substance Registry System: 5'-Methoxy-3',4'-methylenedioxyacetophenone(66922-69-8)

Safety Data

• Hazardous Substances Data: 66922-69-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H10O4/c1-6(11)7-3-8(12-2)10-9(4-7)13-5-14-10/h3-4H,5H2,1-2H3

Upstream product

• 76015-47-9 7-methoxy-benzo[1,3]dioxole-5-carbonyl chloride 
• 105-53-3 diethyl malonate 
• 199742-55-7 1-(7-methoxybenzo[d][1,3]dioxol-5-yl)ethan-1-ol 

Downstream Products

• 1170045-89-2 C₁₇H₁₈N₂O₅S 

Relevant articles and documents

Isocombretastatins A versus combretastatins A: The forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent

Herein is reported a convergent synthesis of isocombretastatins A, a novel class of potent antitubulin agents. These compounds having a 1,1-diarylethylene scaffold constitute the simplest isomers of natural Z-combretastatins A that are easy to synthesize

Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

The present invention provide a compound of formula I or II: or a pharmaceutically acceptable derivative thereof, wherein R1, R2, R3, and R4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; and Src-family kinases, especially Src and Lck kinases. These compounds are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.